SciBase's EIS Technology Selected as Primary Endpoint in NIH Skin Barrier Study

SciBase’s EIS tech is the primary endpoint in a new NIH-led skin barrier study.

What the company is saying

SciBase announces that its Nevisense device and Electrical Impedance Spectroscopy (EIS) technology have been chosen as the primary endpoint in the NIH-led THREAT study, a collaboration with the Swiss Institute of Allergy and Asthma Research. The company frames this as a validation of EIS’s scientific relevance for assessing skin barrier function, emphasizing its use in a high-profile, peer-reviewed research context. The announcement highlights the study’s design, including exposures to sodium lauryl sulfate, synthetic fibers, and 100% cotton controls, and the measurement of skin impedance as the main outcome. CEO Pia Renaudin states that this selection is an important step for expanding the technology’s role in dermatology and skin health research. The company’s tone is confident and focused on scientific credibility, with no mention of commercial or financial outcomes. The communication is targeted at reinforcing SciBase’s position as a leader in dermatological diagnostics and research.

What the data suggests

The announcement confirms that SciBase’s EIS technology is integral to the THREAT study, which is led by the NIH and involves 80 healthy volunteers. The study will compare the effects of everyday exposures—such as detergents, personal care products, and synthetic textiles—on skin barrier function, with 100% cotton used as a control. EIS will be used as the primary endpoint, alongside molecular, microbiome, and inflammatory biomarkers, to objectively measure skin barrier dysfunction. The disclosed facts are limited to the study’s design, sample size, and the selection of SciBase’s technology as a key measurement tool. No financial figures, revenue, or commercial adoption metrics are provided. The evidence supports the claim that SciBase’s technology is scientifically relevant and trusted by leading research institutions, but does not indicate any immediate or quantifiable business impact.

Analysis

The announcement is factual and proportionate, focusing on the selection of SciBase's EIS technology as the primary endpoint in a new NIH-led study. The majority of claims are realised and relate to the study's design, collaborators, and methodology, all of which are supported by the disclosed facts. Only one statement is forward-looking, expressing the CEO's belief that this represents an important step for the company's technology, but this is framed as an aspiration rather than a guarantee of commercial or financial impact. There are no exaggerated claims about immediate business benefits, revenue, or profitability, nor is there any mention of capital outlay or commercialisation timelines. The benefits, if any, from this study are inherently long-term and contingent on future outcomes, but the announcement does not overstate this. The language is measured, and there is no evidence of narrative inflation or overstatement relative to the disclosed facts.

Risk flags

• ●There is a risk that participation in a research study, even one led by the NIH, may not translate into commercial adoption or revenue for SciBase. Academic validation does not guarantee market uptake or reimbursement.
• ●The announcement provides no timeline for study completion or for when results will be published, leaving uncertainty about when, if ever, tangible business benefits might materialize.
• ●The absence of financial or commercial data means investors cannot assess the immediate impact of this collaboration on SciBase’s revenue, profitability, or market share.

Bottom line

SciBase’s EIS technology being selected as the primary endpoint in an NIH-led study signals scientific credibility and positions the company as a trusted partner in dermatological research. The announcement is strictly about research validation, with no disclosed financial, commercial, or operational impact. Investors should see this as a reputational milestone rather than a revenue driver, as the pathway from study participation to commercial benefit is uncertain and likely long-dated. The most important takeaway is that SciBase’s technology is now central to a major international research effort, but concrete business outcomes will depend on future study results and subsequent adoption. For now, this is a positive signal for the company’s scientific standing, not a catalyst for near-term financial performance.

Announcement summary

(STO:SCIB) SciBase Holding AB announced that its Nevisense device and Electrical Impedance Spectroscopy (EIS) technology have been selected as the primary endpoint in a new NIH-led study called THREAT (Testing Harms Related to Exposure to Allergenic Toxins). The study is a collaboration between the National Institute of Health (NIH, US) and the Swiss Institute of Allergy and Asthma Research (SIAF). The THREAT study will use SciBase's EIS technology to explore how environmental exposures impact the skin barrier function. The study design is described in an editorial published in the journal Allergy, titled 'Exploring the Link Between Environmental Exposures and Disease via Direct Challenge.' In the study, healthy subjects will be exposed to common skin products containing sodium lauryl sulfate (SLS), bedding and clothing made of synthetic fibers, or pure contactants free of SLS and apparel/linen made from natural fibers (100% cotton). The effects of these exposures will be measured and compared using skin impedance (EIS) as a marker of skin barrier dysfunction. The study involves 80 healthy volunteers and investigates the effects of everyday exposures, including detergents, personal care products, and synthetic textiles. EIS will be used to monitor changes in skin barrier function over time, alongside molecular, microbiome, and inflammatory biomarkers. The study highlights the scientific relevance of EIS as an objective method for assessing skin barrier function, with potential applications in dermatology, cosmetic research, and skin care product development. Pia Renaudin, CEO of SciBase, stated that the selection of Nevisense for this NIH-led research initiative underscores the scientific relevance of EIS in assessing skin barrier function. She also noted that this represents an important step in expanding the role of SciBase's technology in dermatology and skin health research. The article describing the study design can be found at https://onlinelibrary.wiley.com/doi/10.1111/all.70537.

Disagree with this article?